Detail akcie Vitrolife Rg online

Business Summary: Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Vitrolife AB revenues decreased 5% to SEK3.44B. Net loss applicable to common stockholders totaled SEK5.01B vs. income of SEK513M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Dividend per share remained flat at SEK1.10. Basic Earnings per Share excluding Extraordinary Items decreased from SEK3.79 to -SEK37.01.